LGD-6972
Modify Date: 2024-01-13 20:10:04
LGD-6972 structure
|
Common Name | LGD-6972 | ||
|---|---|---|---|---|
| CAS Number | 1207989-09-0 | Molecular Weight | 702.901 | |
| Density | 1.2±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C43H46N2O5S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of LGD-6972LGD-6972 is a glucagon receptor antagonist. |
| Name | LGD-6972 |
|---|---|
| Synonym | More Synonyms |
| Description | LGD-6972 is a glucagon receptor antagonist. |
|---|---|
| Related Catalog | |
| In Vivo | LGD-6972 has linear plasma pharmacokinetics consistent with once daily dosing that is comparable in healthy and T2DM subjects. Dose-dependent decreases in fasting plasma glucose are observed in all groups with a maximum of 3.15 mM (56.8 mg/dL) on day 14 in T2DM subjects. LGD-6972 also reduces plasma glucose in the postprandial state. Dose-dependent increases in fasting plasma glucagon are observed, but glucagon levels decrease and insulin levels increase after an oral glucose load in T2DM subjects. LGD-6972 is well tolerated at the doses tested without dose-related or clinically meaningful changes in clinical laboratory parameters. No subject experiences hypoglycaemia[1]. |
| References |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Molecular Formula | C43H46N2O5S |
| Molecular Weight | 702.901 |
| Exact Mass | 702.312744 |
| LogP | 8.45 |
| Index of Refraction | 1.616 |
| Storage condition | 2-8℃ |
| Ethanesulfonic acid, 2-[[4-[(2R)-2-[4'-(1,1-dimethylethyl)[1,1'-biphenyl]-4-yl]-3-oxo-3-[(2',4',6'-trimethyl[1,1'-biphenyl]-4-yl)amino]propyl]benzoyl]amino]- |
| 2-[(4-{(2R)-2-[4'-(2-Methyl-2-propanyl)-4-biphenylyl]-3-oxo-3-[(2',4',6'-trimethyl-4-biphenylyl)amino]propyl}benzoyl)amino]ethanesulfonic acid |
| 6IJ842I0Z2 |